We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pulls Evusheld EUA, But AstraZeneca Has Another Antibody in The Wings
FDA Pulls Evusheld EUA, But AstraZeneca Has Another Antibody in The Wings
The FDA has pulled the Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab/cilgavimab) because, the agency says, more than 90 percent of the circulating SARS-CoV-2 variants in the U.S. are now resistant to it.